Clinical Trials Logo

Clinical Trial Summary

Resistance of Plasmodium falciparum toward Artemisinins, the most important drug for the successful treatment of malaria, has been confirmed in Cambodia. There are few reports from neighbouring countries about delayed parasite rates. The investigators therefore aim to assess parasite clearance in malaria patients in central Vietnam when treated according to national standard guidelines.


Clinical Trial Description

General objective To evaluate the efficacy of DHA-PPQ in patients with uncomplicated falciparum malaria in a rural area of Central Vietnam, and to assess the in vitro susceptibility of P.falciparum isolates to DHA and PPQ.

Specific objectives

1. To measure the parasite clearance time in falciparum malaria patients treated with DHA-PPQ.

2. To determine the efficacy of DHA-PPQ at day 42 post-treatment.

3. To assess the in vitro susceptibility of P.falciparum isolates towards DHA and PPQ in Quang Nam Province.

4. To compare genetic profiles of P.falciparum isolates with delayed and those with normal clearance times in order to identify potential markers of resistance; ;


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01775592
Study type Interventional
Source National Institute of Malariology, Parasitology and Entomology, Vietnam
Contact
Status Completed
Phase Phase 4
Start date September 2012
Completion date January 2013

See also
  Status Clinical Trial Phase
Completed NCT01935882 - Low Dose Primaquine for Clearance of Gametocytes Phase 2/Phase 3
Completed NCT01728701 - Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis Phase 1
Completed NCT00914225 - Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya N/A
Completed NCT02895568 - Prevalence Survey of Plasmodium Falciparum Antimalarial Drug Resistance Markers
Recruiting NCT03384498 - Malaria Genetic Surveillance N/A
Completed NCT02259426 - Dihydroartemisinin-piperaquine With Low Dose Primaquine to Reduce Malaria Transmission Phase 3
Completed NCT01465048 - Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe N/A
Active, not recruiting NCT00392015 - NMRC-M3V-Ad-PfCA Vaccine - Clinical Trial 1 Phase 1/Phase 2
Active, not recruiting NCT03138096 - Safety and Protective Efficacy of Pb(PfCS@UIS4) Phase 1/Phase 2
Completed NCT00295581 - PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria Phase 1
Recruiting NCT01322581 - A Longitudinal Systems Biological Analysis of Naturally Acquired Malaria Immunity in Mali
Completed NCT02418962 - Safety and Immunogenicity of Direct Venous Inoculation of a Radiation-attenuated PfSPZ Vaccine in Equatoguinean Adults Phase 1
Not yet recruiting NCT03452475 - Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan Children Phase 3
Completed NCT01160562 - Pilot Study to Estimate the Burden and Distribution of Plasmodium Falciparum Malaria in Kalifabougou, Mali in Preparation for a Prospective Cohort Study of Naturally-Acquired Malaria Immunity
Completed NCT03132402 - ELISA Validation of Hypersensitive Rapid Diagnostic Test Results for Detection of P. Falciparum
Recruiting NCT03172221 - Clinical Performance of the HRP2 HS-RDT for Malaria Diagnosis in Pregnant Women N/A
Not yet recruiting NCT03219281 - Prevalence Survey of Antimalarial Drug Resistance Markers at Sites in India N/A
Completed NCT02090036 - Efficacy and Safety of a Single Low-dose Primaquine for the Clearance of Gametocytes Phase 4
Completed NCT00197054 - A Study to Evaluate Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02A, and RTS,S/AS01B, Two Candidate Malaria Vaccines in Malaria-experienced Adults Living in Western Kenya. Phase 2
Completed NCT01930331 - Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO Phase 4